LH
Labcorp Holdings Inc.
Price Chart
Latest Quote
$281.41
-0.53 (-0.19%)
Current Price
| Previous Close | $281.94 |
| Open | $282.46 |
| Day High | $290.65 |
| Day Low | $279.02 |
| Volume | 264,561 |
Stock Information
| Quarterly Dividend / Yield | $2.88 / 1.02% |
| Shares Outstanding | 82.00M |
| Quarterly Dividend Yield | 1.02% |
| Quarterly Dividend | $2.88 |
| Total Debt | $7.29B |
| Cash Equivalents | $981.10M |
| Revenue | $14.14B |
| Net Income | $941.50M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $23.08B |
| P/E Ratio | 24.95 |
| EPS (TTM) | $11.28 |
| Exchange | NYQ |
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $283.36 | 631,900 |
| 2026-07-16 | $281.94 | 554,800 |
| 2026-07-15 | $271.99 | 809,600 |
| 2026-07-14 | $275.68 | 751,700 |
| 2026-07-13 | $276.68 | 396,300 |
| 2026-07-10 | $276.81 | 433,000 |
| 2026-07-09 | $277.63 | 373,300 |
| 2026-07-08 | $277.74 | 525,500 |
| 2026-07-07 | $283.86 | 615,800 |
| 2026-07-06 | $284.39 | 491,400 |
| 2026-07-02 | $286.98 | 632,900 |
| 2026-07-01 | $283.88 | 722,000 |
| 2026-06-30 | $280.00 | 815,600 |
| 2026-06-29 | $279.58 | 869,800 |
| 2026-06-26 | $271.47 | 1,034,000 |
| 2026-06-25 | $266.34 | 582,300 |
| 2026-06-24 | $265.18 | 632,800 |
| 2026-06-23 | $258.59 | 414,700 |
| 2026-06-22 | $254.43 | 784,900 |
| 2026-06-18 | $255.82 | 1,249,800 |
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
đ° Latest News
CVS Health Corporation (CVS) Soars to 52-Week High, Time to Cash Out?
Zacks âĸ 2026-07-15T13:15:01Z
New Study Reveals Strongest State Economies, Only 1 State Was Better Than Texas
24/7 Wall St. âĸ 2026-07-13T18:18:34Z
Will Strength in Biotechnology Unit Continue to Drive DHR's Growth?
Zacks âĸ 2026-07-08T15:50:00Z
Here's What to Expect From Labcorp Holdingsâ Next Earnings Report
Barchart âĸ 2026-07-02T12:29:28Z
LH or CRL: Which Is the Better Value Stock Right Now?
Zacks âĸ 2026-07-01T15:40:05Z
Omada Health, Inc. (OMDA) Stock Jumps 10.5%: Will It Continue to Soar?
Zacks âĸ 2026-06-29T09:57:00Z
Why Labcorp (LH) Is Up 6.1% After FDA Approval, Medicare Coverage Of ColoSense At-Home Test
Simply Wall St. âĸ 2026-06-27T12:11:08Z
3 Mid-Cap Stocks Walking a Fine Line
StockStory âĸ 2026-06-26T10:48:25Z
Q1 Earnings Highlights: Labcorp (NYSE:LH) Vs The Rest Of The Testing & Diagnostics Services Stocks
StockStory âĸ 2026-06-25T17:05:50Z
Is it the Right Time to Add Labcorp Stock to Your Portfolio?
Zacks âĸ 2026-06-25T15:55:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $9,538,100,000 | $8,997,400,000 | $8,439,200,000 | $7,811,400,000 |
| Cost Of Revenue | $9,939,200,000 | $9,384,500,000 | $8,796,700,000 | $8,155,000,000 |
| Total Revenue | $13,951,700,000 | $13,008,900,000 | $12,161,600,000 | $11,863,900,000 |
| Operating Revenue | $13,974,700,000 | $13,066,900,000 | $12,161,600,000 | $11,863,900,000 |
| Expenses | ||||
| Interest Expense | $224,100,000 | $208,300,000 | $199,600,000 | $179,800,000 |
| Total Expenses | $12,435,500,000 | $11,870,900,000 | $11,037,900,000 | $10,111,700,000 |
| Other Income Expense | $-184,600,000 | $29,800,000 | $-355,200,000 | $-335,000,000 |
| Other Non Operating Income Expenses | $-55,000,000 | $60,200,000 | $15,500,000 | $-32,200,000 |
| Net Non Operating Interest Income Expense | $-224,100,000 | $-208,300,000 | $-199,600,000 | $-179,800,000 |
| Interest Expense Non Operating | $224,100,000 | $208,300,000 | $199,600,000 | $179,800,000 |
| Operating Expense | $2,496,300,000 | $2,486,400,000 | $2,241,200,000 | $1,956,700,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $876,500,000 | $746,000,000 | $379,200,000 | $1,002,000,000 |
| Net Interest Income | $-224,100,000 | $-208,300,000 | $-199,600,000 | $-179,800,000 |
| Normalized Income | $968,725,900 | $768,591,000 | $626,261,700 | $1,251,942,379 |
| Net Income From Continuing And Discontinued Operation | $876,500,000 | $746,000,000 | $418,000,000 | $1,279,100,000 |
| Total Operating Income As Reported | $1,384,700,000 | $1,086,700,000 | $725,600,000 | $1,436,500,000 |
| Net Income Common Stockholders | $876,500,000 | $746,000,000 | $418,000,000 | $1,279,100,000 |
| Net Income | $876,500,000 | $746,000,000 | $418,000,000 | $1,279,100,000 |
| Net Income Including Noncontrolling Interests | $877,700,000 | $747,100,000 | $419,200,000 | $1,280,600,000 |
| Net Income Discontinuous Operations | $0 | $0 | $38,800,000 | $277,100,000 |
| Net Income Continuous Operations | $877,700,000 | $747,100,000 | $380,400,000 | $1,003,500,000 |
| Pretax Income | $1,107,500,000 | $959,500,000 | $568,900,000 | $1,237,400,000 |
| Special Income Charges | $-131,500,000 | $-51,300,000 | $-398,100,000 | $-315,700,000 |
| Earnings From Equity Interest | $-13,300,000 | $-1,400,000 | $-1,400,000 | $5,400,000 |
| Operating Income | $1,516,200,000 | $1,138,000,000 | $1,123,700,000 | $1,752,200,000 |
| Depreciation Amortization Depletion Income Statement | $280,000,000 | $256,400,000 | $219,800,000 | $193,600,000 |
| Depreciation And Amortization In Income Statement | $280,000,000 | $256,400,000 | $219,800,000 | $193,600,000 |
| Amortization Of Intangibles Income Statement | $280,000,000 | $256,400,000 | $219,800,000 | $193,600,000 |
| Gross Profit | $4,012,500,000 | $3,624,400,000 | $3,364,900,000 | $3,708,900,000 |
| Per Share | ||||
| Diluted EPS | $10.46 | $8.84 | $4.77 | $13.97 |
| Basic EPS | $10.54 | $8.89 | $4.80 | $14.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $-24,074,100 | $-6,409,000 | $-122,238,300 | $-58,257,621 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $2,129,000,000 | $1,840,300,000 | $1,715,100,000 | $2,262,600,000 |
| Total Unusual Items | $-116,300,000 | $-29,000,000 | $-369,300,000 | $-308,200,000 |
| Total Unusual Items Excluding Goodwill | $-116,300,000 | $-29,000,000 | $-369,300,000 | $-308,200,000 |
| Reconciled Depreciation | $681,100,000 | $643,500,000 | $577,300,000 | $537,200,000 |
| EBITDA (Bullshit earnings) | $2,012,700,000 | $1,811,300,000 | $1,345,800,000 | $1,954,400,000 |
| EBIT | $1,331,600,000 | $1,167,800,000 | $768,500,000 | $1,417,200,000 |
| Diluted Average Shares | $83,800,000 | $84,400,000 | $87,600,000 | $91,600,000 |
| Basic Average Shares | $83,200,000 | $83,900,000 | $87,100,000 | $91,100,000 |
| Diluted NI Availto Com Stockholders | $876,500,000 | $746,000,000 | $418,000,000 | $1,279,100,000 |
| Minority Interests | $-1,200,000 | $-1,100,000 | $-1,200,000 | $-1,500,000 |
| Tax Provision | $229,800,000 | $212,400,000 | $188,500,000 | $233,900,000 |
| Impairment Of Capital Assets | $4,300,000 | $5,300,000 | $349,000,000 | $261,700,000 |
| Restructuring And Mergern Acquisition | $127,200,000 | $46,000,000 | $49,100,000 | $54,000,000 |
| Gain On Sale Of Security | $15,200,000 | $22,300,000 | $28,800,000 | $7,500,000 |
| Amortization | $280,000,000 | $256,400,000 | $219,800,000 | $193,600,000 |
| Selling General And Administration | $2,216,300,000 | $2,230,000,000 | $2,021,400,000 | $1,763,100,000 |
Fetched: 2026-07-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,765,700,000 | $-1,806,400,000 | $-1,609,500,000 | $850,000,000 |
| Total Assets | $18,392,700,000 | $18,379,000,000 | $16,725,100,000 | $20,155,100,000 |
| Total Non Current Assets | $14,372,200,000 | $13,572,500,000 | $12,959,700,000 | $15,529,400,000 |
| Other Non Current Assets | $751,300,000 | $652,200,000 | $536,500,000 | $3,416,600,000 |
| Goodwill And Other Intangible Assets | $10,385,500,000 | $9,858,600,000 | $9,484,500,000 | $9,246,600,000 |
| Other Intangible Assets | $3,596,000,000 | $3,488,900,000 | $3,342,000,000 | $3,122,900,000 |
| Current Assets | $4,020,500,000 | $4,806,500,000 | $3,765,400,000 | $4,625,000,000 |
| Other Current Assets | $692,800,000 | $697,600,000 | $655,300,000 | $610,400,000 |
| Inventory | $534,700,000 | $493,200,000 | $474,600,000 | $470,600,000 |
| Receivables | $2,260,700,000 | $2,097,000,000 | $2,098,700,000 | $1,997,300,000 |
| Other Receivables | $156,900,000 | $152,900,000 | $185,400,000 | $211,800,000 |
| Accounts Receivable | $2,103,800,000 | $1,944,100,000 | $1,913,300,000 | $1,785,500,000 |
| Allowance For Doubtful Accounts Receivable | $-36,400,000 | $-44,700,000 | $-32,700,000 | $-30,800,000 |
| Gross Accounts Receivable | $2,140,200,000 | $1,988,800,000 | $1,946,000,000 | $1,816,300,000 |
| Cash Cash Equivalents And Short Term Investments | $532,300,000 | $1,518,700,000 | $536,800,000 | $320,600,000 |
| Cash And Cash Equivalents | $532,300,000 | $1,518,700,000 | $536,800,000 | $320,600,000 |
| Non Current Deferred Assets | - | - | $0 | $6,400,000 |
| Non Current Deferred Taxes Assets | - | - | $0 | $6,400,000 |
| Assets Held For Sale Current | - | - | $0 | $1,226,100,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $5,052,400,000 | $4,812,800,000 | $4,517,700,000 | $5,019,500,000 |
| Total Debt | $6,526,000,000 | $7,272,800,000 | $5,954,200,000 | $6,246,400,000 |
| Long Term Debt And Capital Lease Obligation | $5,830,200,000 | $6,081,800,000 | $4,782,200,000 | $5,775,300,000 |
| Long Term Debt | $5,084,600,000 | $5,331,200,000 | $4,054,700,000 | $5,038,800,000 |
| Current Debt And Capital Lease Obligation | $695,800,000 | $1,191,000,000 | $1,172,000,000 | $471,100,000 |
| Current Debt | $500,100,000 | $1,000,300,000 | $999,800,000 | $301,300,000 |
| Other Current Borrowings | $300,000 | $400,000 | $1,100,000 | $1,700,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $9,756,000,000 | $10,312,500,000 | $8,834,600,000 | $10,039,600,000 |
| Total Non Current Liabilities Net Minority Interest | $6,932,500,000 | $6,982,300,000 | $5,609,400,000 | $6,961,100,000 |
| Other Non Current Liabilities | $112,100,000 | $136,200,000 | $142,300,000 | $161,300,000 |
| Derivative Product Liabilities | $274,000,000 | $142,700,000 | $53,700,000 | $45,700,000 |
| Non Current Deferred Liabilities | $605,000,000 | $515,600,000 | $525,300,000 | $640,300,000 |
| Non Current Deferred Taxes Liabilities | $454,500,000 | $383,100,000 | $417,900,000 | $543,400,000 |
| Current Liabilities | $2,823,500,000 | $3,330,200,000 | $3,225,200,000 | $3,078,500,000 |
| Current Deferred Liabilities | $439,100,000 | $392,200,000 | $421,700,000 | $310,600,000 |
| Current Notes Payable | $499,800,000 | $999,900,000 | $998,700,000 | $299,600,000 |
| Payables And Accrued Expenses | $1,264,700,000 | $1,251,600,000 | $1,200,100,000 | $1,194,600,000 |
| Payables | $1,001,100,000 | $1,028,500,000 | $955,000,000 | $957,800,000 |
| Total Tax Payable | $160,300,000 | $152,700,000 | $127,500,000 | $105,600,000 |
| Accounts Payable | $840,800,000 | $875,800,000 | $827,500,000 | $852,200,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $241,300,000 |
| Other Current Liabilities | - | - | - | $657,600,000 |
| Equity | ||||
| Common Stock Equity | $8,619,800,000 | $8,052,200,000 | $7,875,000,000 | $10,096,600,000 |
| Total Equity Gross Minority Interest | $8,636,700,000 | $8,066,500,000 | $7,890,500,000 | $10,115,500,000 |
| Stockholders Equity | $8,619,800,000 | $8,052,200,000 | $7,875,000,000 | $10,096,600,000 |
| Gains Losses Not Affecting Retained Earnings | $-27,600,000 | $-261,600,000 | $-59,300,000 | $-493,200,000 |
| Other Equity Adjustments | $-27,600,000 | $-261,600,000 | $-59,300,000 | $-493,200,000 |
| Retained Earnings | $8,639,900,000 | $8,303,400,000 | $7,888,200,000 | $10,581,700,000 |
| Long Term Equity Investment | $153,900,000 | $16,300,000 | $26,900,000 | $65,700,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $18,900,000 |
| Other | ||||
| Ordinary Shares Number | $82,200,000 | $83,400,000 | $83,900,000 | $88,200,000 |
| Share Issued | $82,200,000 | $83,400,000 | $83,900,000 | $88,200,000 |
| Tangible Book Value | $-1,765,700,000 | $-1,806,400,000 | $-1,609,500,000 | $850,000,000 |
| Invested Capital | $14,204,500,000 | $14,383,700,000 | $12,929,500,000 | $15,436,700,000 |
| Working Capital | $1,197,000,000 | $1,476,300,000 | $540,200,000 | $1,546,500,000 |
| Capital Lease Obligations | $941,300,000 | $941,300,000 | $899,700,000 | $906,300,000 |
| Total Capitalization | $13,704,400,000 | $13,383,400,000 | $11,929,700,000 | $15,135,400,000 |
| Minority Interest | $16,900,000 | $14,300,000 | $15,500,000 | $18,900,000 |
| Additional Paid In Capital | $0 | $2,800,000 | $38,400,000 | $0 |
| Capital Stock | $7,500,000 | $7,600,000 | $7,700,000 | $8,100,000 |
| Common Stock | $7,500,000 | $7,600,000 | $7,700,000 | $8,100,000 |
| Employee Benefits | $111,200,000 | $106,000,000 | $105,900,000 | $97,200,000 |
| Long Term Capital Lease Obligation | $745,600,000 | $750,600,000 | $727,500,000 | $736,500,000 |
| Current Deferred Revenue | $439,100,000 | $392,200,000 | $421,700,000 | $310,600,000 |
| Current Capital Lease Obligation | $195,700,000 | $190,700,000 | $172,200,000 | $169,800,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $423,900,000 | $495,400,000 | $431,400,000 | $444,600,000 |
| Current Accrued Expenses | $263,600,000 | $223,100,000 | $245,100,000 | $236,800,000 |
| Investments And Advances | $153,900,000 | $16,300,000 | $26,900,000 | $65,700,000 |
| Goodwill | $6,789,500,000 | $6,369,700,000 | $6,142,500,000 | $6,123,700,000 |
| Net PPE | $3,081,500,000 | $3,045,400,000 | $2,911,800,000 | $2,794,100,000 |
| Accumulated Depreciation | $-3,270,100,000 | $-3,071,000,000 | $-2,905,100,000 | $-2,584,400,000 |
| Gross PPE | $6,351,600,000 | $6,116,400,000 | $5,816,900,000 | $5,378,500,000 |
| Leases | $577,900,000 | $550,600,000 | $515,800,000 | $484,000,000 |
| Construction In Progress | $381,500,000 | $333,400,000 | $342,200,000 | $306,500,000 |
| Other Properties | $803,900,000 | $784,500,000 | $737,100,000 | $738,100,000 |
| Machinery Furniture Equipment | $3,329,200,000 | $3,237,200,000 | $3,039,200,000 | $2,741,600,000 |
| Buildings And Improvements | $1,171,600,000 | $1,098,400,000 | $1,083,800,000 | $1,009,800,000 |
| Land And Improvements | $87,500,000 | $112,300,000 | $98,800,000 | $98,500,000 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $534,700,000 | $493,200,000 | $474,600,000 | $470,600,000 |
| Treasury Shares Number | - | - | $0 | - |
| Line Of Credit | - | - | - | - |
Fetched: 2026-07-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,206,000,000 | $1,095,900,000 | $874,100,000 | $1,526,600,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,640,500,000 | $1,585,800,000 | $1,327,700,000 | $1,955,900,000 |
| Cash From Discontinued Operating Activities | $0 | $0 | $125,400,000 | $191,100,000 |
| Cash Flow From Continuing Operating Activities | $1,640,500,000 | $1,585,800,000 | $1,202,300,000 | $1,764,800,000 |
| Investing Activities | ||||
| Capital Expenditure | $-434,500,000 | $-489,900,000 | $-453,600,000 | $-429,300,000 |
| Investing Cash Flow | $-1,194,000,000 | $-1,366,800,000 | $-1,171,500,000 | $-1,652,200,000 |
| Cash From Discontinued Investing Activities | $0 | $0 | $-24,700,000 | $-52,600,000 |
| Cash Flow From Continuing Investing Activities | $-1,194,000,000 | $-1,366,800,000 | $-1,146,800,000 | $-1,599,600,000 |
| Net Other Investing Changes | $8,000,000 | $2,000,000 | $600,000 | $1,400,000 |
| Capital Expenditure Reported | $-434,500,000 | $-489,900,000 | $-453,600,000 | $-429,300,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-450,000,000 | $-250,100,000 | $-1,000,000,000 | $-1,100,000,000 |
| Financing Cash Flow | $-1,457,000,000 | $779,900,000 | $-59,300,000 | $-1,322,200,000 |
| Cash From Discontinued Financing Activities | $0 | $0 | $1,499,700,000 | $0 |
| Cash Flow From Continuing Financing Activities | $-1,457,000,000 | $779,900,000 | $-1,559,000,000 | $-1,322,200,000 |
| Net Other Financing Charges | $179,400,000 | $216,900,000 | $-59,400,000 | $-77,600,000 |
| Cash Dividends Paid | $-240,700,000 | $-243,100,000 | $-254,000,000 | $-195,200,000 |
| Common Stock Dividend Paid | $-240,700,000 | $-243,100,000 | $-254,000,000 | $-195,200,000 |
| Net Common Stock Issuance | $-450,000,000 | $-250,100,000 | $-1,000,000,000 | $-1,100,000,000 |
| Issuance Of Capital Stock | - | - | $54,400,000 | $50,600,000 |
| Common Stock Issuance | - | - | $54,400,000 | $50,600,000 |
| Other | ||||
| Repayment Of Debt | $-1,064,800,000 | $-3,463,700,000 | $-2,788,200,000 | $-787,400,000 |
| Issuance Of Debt | $64,800,000 | $4,463,700,000 | $2,488,200,000 | $787,400,000 |
| Interest Paid Supplemental Data | $217,700,000 | $209,200,000 | $221,500,000 | $196,700,000 |
| Income Tax Paid Supplemental Data | $171,100,000 | $215,400,000 | $206,800,000 | $474,900,000 |
| End Cash Position | $532,300,000 | $1,518,700,000 | $536,800,000 | $320,600,000 |
| Beginning Cash Position | $1,518,700,000 | $536,800,000 | $430,000,000 | $1,472,700,000 |
| Effect Of Exchange Rate Changes | $24,100,000 | $-17,000,000 | $9,900,000 | $-24,200,000 |
| Changes In Cash | $-1,010,500,000 | $998,900,000 | $96,900,000 | $-1,127,900,000 |
| Proceeds From Stock Option Exercised | $54,300,000 | $56,200,000 | $54,400,000 | $50,600,000 |
| Common Stock Payments | $-450,000,000 | $-250,100,000 | $-1,000,000,000 | $-1,100,000,000 |
| Net Issuance Payments Of Debt | $-1,000,000,000 | $1,000,000,000 | $-300,000,000 | $0 |
| Net Long Term Debt Issuance | $-1,000,000,000 | $1,000,000,000 | $-300,000,000 | $0 |
| Long Term Debt Payments | $-1,064,800,000 | $-3,463,700,000 | $-2,788,200,000 | $-787,400,000 |
| Long Term Debt Issuance | $64,800,000 | $4,463,700,000 | $2,488,200,000 | $787,400,000 |
| Net Investment Purchase And Sale | $-192,400,000 | $-55,000,000 | $-29,000,000 | $-9,300,000 |
| Purchase Of Investment | $-192,400,000 | $-55,000,000 | $-29,000,000 | $-17,400,000 |
| Net Business Purchase And Sale | $-575,100,000 | $-823,900,000 | $-664,800,000 | $-1,162,400,000 |
| Sale Of Business | $6,900,000 | $15,100,000 | $6,700,000 | $1,600,000 |
| Purchase Of Business | $-582,000,000 | $-839,000,000 | $-671,500,000 | $-1,164,000,000 |
| Change In Working Capital | $-526,100,000 | $-154,100,000 | $-361,900,000 | $-376,200,000 |
| Change In Other Working Capital | $34,600,000 | $-24,600,000 | $105,500,000 | $67,800,000 |
| Change In Payables And Accrued Expense | $-383,100,000 | $-40,500,000 | $-365,600,000 | $-177,500,000 |
| Change In Accrued Expense | $-330,300,000 | $-112,600,000 | $-323,200,000 | $-462,900,000 |
| Change In Payable | $-52,800,000 | $72,100,000 | $-42,400,000 | $285,400,000 |
| Change In Account Payable | $-52,800,000 | $72,100,000 | $-42,400,000 | $285,400,000 |
| Change In Prepaid Assets | $-25,200,000 | $-54,500,000 | $-25,800,000 | $-244,100,000 |
| Change In Inventory | $-30,200,000 | $-12,600,000 | $-700,000 | $-45,500,000 |
| Change In Receivables | $-122,200,000 | $-21,900,000 | $-75,300,000 | $23,100,000 |
| Changes In Account Receivables | $-125,500,000 | $-52,300,000 | $-103,800,000 | $46,500,000 |
| Other Non Cash Items | $380,100,000 | $247,400,000 | $206,900,000 | $195,500,000 |
| Stock Based Compensation | $125,800,000 | $116,700,000 | $128,700,000 | $116,800,000 |
| Asset Impairment Charge | $4,300,000 | $5,300,000 | $349,000,000 | $261,700,000 |
| Deferred Tax | $97,600,000 | $-20,100,000 | $-78,100,000 | $26,300,000 |
| Deferred Income Tax | $97,600,000 | $-20,100,000 | $-78,100,000 | $26,300,000 |
| Depreciation Amortization Depletion | $681,100,000 | $643,500,000 | $577,300,000 | $537,200,000 |
| Depreciation And Amortization | $681,100,000 | $643,500,000 | $577,300,000 | $537,200,000 |
| Amortization Cash Flow | $280,000,000 | $256,400,000 | $219,800,000 | $193,600,000 |
| Amortization Of Intangibles | $280,000,000 | $256,400,000 | $219,800,000 | $193,600,000 |
| Depreciation | $401,100,000 | $387,100,000 | $357,500,000 | $343,600,000 |
| Net Income From Continuing Operations | $877,700,000 | $747,100,000 | $380,400,000 | $1,003,500,000 |
| Cash Flow From Discontinued Operation | - | $0 | $0 | $-109,400,000 |
| Sale Of Investment | - | $0 | $6,700,000 | $8,100,000 |
| Net Short Term Debt Issuance | - | - | - | $787,400,000 |
| Short Term Debt Payments | - | - | - | $-787,400,000 |
| Short Term Debt Issuance | - | - | - | $787,400,000 |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-07-10